Related Experiment Video
Updated: Mar 18, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice
Published on: August 25, 2012
Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study
Marc Schläppi1, Christoph Ewald2, Jürgen Johannes Kuehn3
11 Cantonal Hospital St Gallen, Switzerland.
Purpose:
So-called spontaneous remissions in cancer often seem to occur after febrile events. Mistletoe preparations (MPs) are used off-label intravenously to induce fever within concepts of integrative oncology. We wanted to investigate the frequency of febrile reactions and safety related to intravenously applied MPs (IAMPs).
Methods:
This was a retrospective analysis of data from consecutive cancer patients who were treated in 2 anthroposophic hospitals with IAMPs. The main outcome parameter was the rate of core temperature increase to ≥38.5°C within 24 hours after IAMPs. Secondary outcome parameters were Common Toxicity Criteria for Adverse Events (CTCAE; version 4.0).
Results:
59 patients, with in total 567 IAMPs, were analyzed; 45 patients (76%, 95% CI = 65%-87%) had an increase of core temperature to ≥38.5°C after at least 1 treatment. Mean increase in temperature was 1.5°C ± 0.8°C. Adverse events were mostly fever-related symptoms (headache, joint pain, shivering). Grade 1 allergic reactions were documented in 0.6% of treatments. CTCAEs grade 3 to 5 did not occur; 38/59 patients had advanced and/or metastatic disease.
Conclusion:
IAMPs resulted in febrile reactions to >38.5°C in the majority of patients and can be considered as safe. Adverse events were mostly related to fever and were not severe.
Insights
Intravenously applied mistletoe preparations (IAMPs) frequently induce fever in cancer patients, with most side effects being mild and fever-related. This integrative oncology approach appears safe for inducing febrile reactions.
Area of Science:
- Integrative Oncology
- Complementary Cancer Therapies
- Pharmacology
Background:
- Spontaneous cancer remissions are sometimes linked to fever.
- Mistletoe preparations (MPs) are used in integrative oncology to induce fever.
- Intravenous administration of MPs (IAMPs) is an off-label use.
Purpose of the Study:
- To investigate the frequency of fever induction by IAMPs.
- To assess the safety of IAMPs in cancer patients.
- To document adverse events associated with IAMPs.
Main Methods:
- Retrospective analysis of cancer patients treated with IAMPs in two anthroposophic hospitals.
- Core temperature increase to ≥38.5°C within 24 hours post-IAMP was the primary outcome.
- Common Toxicity Criteria for Adverse Events (CTCAE) v4.0 was used for safety assessment.
Main Results:
- 76% of 59 patients experienced a temperature increase to ≥38.5°C after at least one IAMP treatment.
- The mean temperature increase was 1.5°C ± 0.8°C.
- Adverse events were primarily fever-related (headache, joint pain, shivering); no CTCAE grade 3-5 events occurred. 0.6% of treatments had Grade 1 allergic reactions.
Conclusions:
- IAMPs effectively induce febrile reactions in the majority of cancer patients.
- IAMPs can be considered safe for inducing fever, with mostly mild, fever-related adverse events.
- The study included patients with advanced and metastatic disease, indicating potential application in later-stage cancer care.
More Related Videos
06:45In Vitro and In Vivo Delivery of Magnetic Nanoparticle Hyperthermia Using a Custom-Built Delivery System
Published on: July 2, 2020
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Related Concept Videos
Tumor Immunotherapy
Decreased Body Temperature
Increased Body Temperature
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Homeostatic Imbalances in Body Temperature
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...